213 related articles for article (PubMed ID: 34439266)
1. A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Uckun FM; Lin TL; Mims AS; Patel P; Lee C; Shahidzadeh A; Shami PJ; Cull E; Cogle CR; Watts J
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439266
[TBL] [Abstract][Full Text] [Related]
2.
Watts J; Lin TL; Mims A; Patel P; Lee C; Shahidzadeh A; Shami P; Cull E; Cogle CR; Wang E; Uckun FM
Front Oncol; 2021; 11():806243. PubMed ID: 35096610
[TBL] [Abstract][Full Text] [Related]
3. Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436.
Uckun FM; Watts J; Mims AS; Patel P; Wang E; Shami PJ; Cull E; Lee C; Cogle CR; Lin TL
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771451
[TBL] [Abstract][Full Text] [Related]
4. A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Uckun FM; Cogle CR; Lin TL; Qazi S; Trieu VN; Schiller G; Watts JM
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31888052
[TBL] [Abstract][Full Text] [Related]
5. CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients.
Uckun FM; Watts J
Front Aging; 2021; 2():757276. PubMed ID: 35822053
[TBL] [Abstract][Full Text] [Related]
6. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract][Full Text] [Related]
7. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
Ravandi F; Subklewe M; Walter RB; Vachhani P; Ossenkoppele G; Buecklein V; Döhner H; Jongen-Lavrencic M; Baldus CD; Fransecky L; Pardee TS; Kantarjian H; Yen PK; Mukundan L; Panwar B; Yago MR; Agarwal S; Khaldoyanidi SK; Stein A
Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38712673
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
Ravandi F; Bashey A; Foran J; Stock W; Mawad R; Short N; Yilmaz M; Kantarjian H; Odenike O; Patel A; Garcha R; Ainsworth WB; Clynes R; Kanodia J; Ding Y; Li H; Kye S; Mims A
Blood Adv; 2023 Nov; 7(21):6492-6505. PubMed ID: 37647601
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
[TBL] [Abstract][Full Text] [Related]
11. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
Shafer D; Kagan AB; Rudek MA; Kmieciak M; Tombes MB; Shrader E; Bandyopadhyay D; Hudson D; Sankala H; Weir C; Lancet JE; Grant S
Cancer Chemother Pharmacol; 2023 Mar; 91(3):281-290. PubMed ID: 36864346
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
14. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Sallman DA; Kerre T; Havelange V; Poiré X; Lewalle P; Wang ES; Brayer JB; Davila ML; Moors I; Machiels JP; Awada A; Alcantar-Orozco EM; Borissova R; Braun N; Dheur MS; Gilham DE; Lonez C; Lehmann FF; Flament A
Lancet Haematol; 2023 Mar; 10(3):e191-e202. PubMed ID: 36764323
[TBL] [Abstract][Full Text] [Related]
15. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
16. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
17. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Giles FJ; Stopeck AT; Silverman LR; Lancet JE; Cooper MA; Hannah AL; Cherrington JM; O'Farrell AM; Yuen HA; Louie SG; Hong W; Cortes JE; Verstovsek S; Albitar M; O'Brien SM; Kantarjian HM; Karp JE
Blood; 2003 Aug; 102(3):795-801. PubMed ID: 12649163
[TBL] [Abstract][Full Text] [Related]
18. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.
Chichili GR; Huang L; Li H; Burke S; He L; Tang Q; Jin L; Gorlatov S; Ciccarone V; Chen F; Koenig S; Shannon M; Alderson R; Moore PA; Johnson S; Bonvini E
Sci Transl Med; 2015 May; 7(289):289ra82. PubMed ID: 26019218
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
[TBL] [Abstract][Full Text] [Related]
20. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG
Leukemia; 2017 Dec; 31(12):2799-2806. PubMed ID: 28546581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]